MDR_Button Contact_Button News_Button  

CBT-1®  Publications

New Publications:

Current Cancer Drug Targets, 2016, 16, 261-274
Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma
Marilù Fanelli, Claudia Maria Hattinger, Serena Vella, Elisa Tavanti1, Francesca Michelacci, Beth Gudeman, Daryl Barnett, Piero Picci and Massimo Serra

Article excerpt:

"...we showed that OS cell lines overexpressing ABCB1 and ABCC1 were also crossresistant to vinorelbine, taxotere (docetaxel) and etoposide. Combined treatments with CBT-1 and these three drugs produced some relevant chemosensitization effects, indicating that CBT-1 can increase cellular sensitivity also to some of the agents used in second-line OS treatments, which are ABCB1 and/or ABCC1 substrates. Therefore, drugs which, as CBT-1, target or inhibit these transporters, may significantly enhance the moderate efficacy of the presently used rescue protocols.

Moreover, it has recently been shown that targeting specific protein kinases with tyrosine kinase inhibitors represent an interesting new therapeutic option for OS treatment [5, 6, 38-40]. However, it has to be taken into account that several tyrosine kinase inhibitors are ABC substrates [41-43]. Therefore, CBT-1 treatment may also be considered to increase sensitivity to these drugs in ABC overexpressing patients."

Publication Archive:

Investigational New Drugs September 2014 Date: 07 Sep 2014
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
Valeria Sero, Elisa Tavanti, Serena Vella, Claudia Maria Hattinger, Marilù Fanelli, Francesca Michelacci, Rogier Versteeg, Barbara Valsasina, Beth Gudeman, Piero Picci, Massimo Serra

British Journal of Cancer 109, 2607-2618 (12 November 2013) | doi:10.1038/bjc.2013.643
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
E Tavanti, V Sero, S Vella, M Fanelli, F Michelacci, L Landuzzi, G Magagnoli,R Versteeg, P Picci, C M Hattinger and M Serra

Kelly, R. J., Robey, R. W., Chen, C. C., Draper, D., Luchenko, V., Barnett, D., Oldham, R. K., Caluag, Z., Frye, A. R., Steinberg, S. M., Fojo, T., Bates, S. E.,  A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1® in Combination With Paclitaxel in Solid Tumors, 2012, The Oncologist, 17, 2012-0080

Robey, R. W., Shukla, S., Finely, E. M., Oldham, R. K., Barnett, D., Ambudkar, S. V., Fojo, T., Bates, S. E., Inhibition of P-glycoprotein (ABCB1)-and Multidrug Resistance-Associated Protein 1 (ABCC1)-Mediated Transport By The Orally Administered Inhibitor, CBT-1®, 2008, Biochemical Pharmacology, 75, 6, 1302-1312

Oldham, R. K., Reid, W. K., and Barnett, D., Phase I Study of CBT-1® and Taxol® in Patients With Taxol® Resistant Cancers, 2000, Cancer Biotherapy & Radiopharmaceuticals, 15, 153-159

Oldham, R. K., Reid, W. K., Preisler, H. D., and Barnett, D., A Phase I Pharmacokinetic Study of CBT-1® as a Multidrug Resistance Modulator in the Treatment of Patients With Advanced Cancer, 1998, Cancer Biotherapy & Radiopharmaceuticals, 13, 71-80

Poster Presentation:
New England Science Symposium; Oral Presenter Elizabeth Finely; Robey, R., Bates, S.,  Fojo, T., Barnett, D., Oldham, R., Polgar, O., Orbzut, T., Ediriwickrema, L.; The Natural Product CBT-1® Inhibits Pgp and MRP1-Mediated Drug Resistance; 2007

AAPS National Biotechnology Conference; Robey, R., Shukla, S., Finely, Oldham, R., Barnett, D., Ambudkar, S., Fojo, T., Bates, S.; The Natural Product CBT-1® Inhibits Pgp and MRP1-Mediated Drug Resistance; 2007

International Lung Cancer Conference; Oldham, R.K., Barnett, D., Ramos, Z.; A Phase II Study of Taxol®/CBT-1®, an MDR Modulator; 2002

American Society of Clinical Oncology (ASCO); Oldham, R.K., Barnett, D., Ramos, Z.; A Phase II Study of Paclitaxel/CBT-1®, an MDR Modulator; 2003     



Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.


© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions